Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome. In March 2023, trofinetide received regulatory approval in the United States under the trade name Daybue for the treatment of Rett syndrome in pediatric patients. Neuren’s preclinical pipeline also includes NNZ-2591, a second-generation molecule targeting Angelman syndrome and other neurodevelopmental conditions. These programs leverage the company’s expertise in peptide biology and neuroinflammation.

Founded in 1998 as a spin-out from Australia’s Royal Children’s Hospital and affiliated research institutes, Neuren has established partnerships to support clinical development and commercialization. The company collaborates with international regulatory bodies and contract research organizations to conduct Phase II and Phase III studies across North America, Europe and Australia. Headquartered in Melbourne, Neuren draws on a team of experienced drug development professionals to advance its mission of transforming the lives of patients with serious neurological disorders.

Key Stats

• Today's Range: C$8.88 to C$8.88
• 50-Day Range: C$8.22 to C$8.88
• 52-Week Range: C$7.63 to C$14.80
• Volume: N/A
• Average Volume: 975 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Neuren Pharmaceuticals Stock Analysis - MarketRank™

Neuren Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Neuren Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuren Pharmaceuticals is -992.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuren Pharmaceuticals is -992.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuren Pharmaceuticals has recently decreased by 13.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuren Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Neuren Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Neuren Pharmaceuticals has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Neuren Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuren Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

1.74% of the stock of Neuren Pharmaceuticals is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NURPF
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: (139) 092-0480
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A